 |
FibromyalgiaThere is no known cause for fibromyalgia, but studies are searching for treatments. Similarities have been noted between fibromyalgia’s clinical features and the adult GH-deficiency syndrome. Review current research and medical articles on fibromyalgia, which examine hormone modulation’s therapeutic potential on this condition. Growth Hormone and Insulin-Like Growth Factor-1 Concentrations in Women with Fibromyalgia.pdf
In this sample of
premenopausal women with FM,
the activity of the GH-IGF-1
axis was similar to that of
healthy controls. Increases
in age and obesity were both
strongly associated with
lower activity of this axis,
suggesting that these
factors must be considered
when studying activity of
the GH-IGF-1 axis in FM. Fibromyalgia: Symptom Constellation and Potential Therapeutic Options.pdf
The findings of this
study suggest the
somatotrophic axis may be
involved in the etiology and
the treatment of this
disorder. Those diagnosed
with FM respond to various
stressors with increased
disruption of their
physiological homeostasis. Neuroendocrine Abnormalities in Fibromyalgia.pdf
This review summarizes
the available data on the
neuroendocrine function in
fibromyalgia, including data
on hormone secretion,
circadian phase, and
autonomic nervous system
function.
Adult Growth Hormone
Deficiency in Patients with
Fibromyalgia.pdf
Twenty patients with
fibromyalgia syndrome (FMS)
and 20 matched healthy
controls were subjected to
an exercise stress test
above their anaerobic
threshold. The results of
this study suggest the
possibility of a
perturbation in hormonal
response to exercise in
patients with FMS. Decreased Nocturnal Levels of Prolactin and Growth Hormone in Women with Fibromyalgia.pdf
These data demonstrate
altered functioning of both
the somatotropic and
lactotropic axes during
sleep in FM and support the
hypothesis that dysregulated
neuroendocrine systems
during sleep may play a role
in the pathophysiology of
FM.
The data from this study
show that patients with FM
exhibited a marked decrease
in spontaneous GH secretion,
but normal pituitary
responsiveness to
exogenously administered
GHRH, thus suggesting the
existence of an alteration
at the hypothalamic level in
the neuroendocrine control
of GH in these patients.
Furthermore, our finding of
increased IGF-1 and IGFBP-3
levels after GH treatment,
over 4 days, opens up the
possibility of testing the
therapeutic potential of hGH
in patients with FM.
The results of this study
suggest that growth hormone
secretion is decreased in
patients with FM.
Substitution therapy with
low doses of growth hormone
may be worth evaluating in
the treatment of FM.
This study concluded that
women with fibromyalgia and
low IGF-1 levels experienced
an improvement in their
overall symptomatology and
number of tender points
after 9 months of daily
growth hormone therapy. This
suggests that a secondary
growth hormone deficiency
may be responsible for some
of the symptoms of
fibromyalgia.
This study concluded that
many, but not all, patients
with FM have low levels of
IGF-I that cannot be
explained by clinical
associations. These results
suggest that low IGF-I
levels in patients with FM
are a secondary phenomenon
due to
hypothalamic-pituitary-GH
axis dysfunction.
This study concluded that
major secretory deficiencies
were not documented.
However, they say that the
power of their study does
not allow us to discard the
role of minor secretory
deficiencies of human growth
hormone in FM.
|
